Agreement: I Agree Body: Dear Editor: We read with great interest a randomised controlled trial comparing 3 months versus 12 months of dual antiplatelet therapy (DAPT) after coronary artery bypass grafting (CABG). The authors are to be congratulated for conducting a large, multicentre, double-blind non-inferiority trial that showed that a shortened DAPT regimen preserved saphenous vein graft patency but markedly reduced clinically relevant bleeding. These data have important implications to opti